Non-squamous non-small cell lung cancer
Conditions
Interventions
After Cisplatin or Carboplatin + Pemetrexed (500mg/m2) + Bevacizumab (15mg/kg) day 1 q3w 3 cycles, lung resection with lymph node dissection
Sponsors
UOEH
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically or pathologically proven non-squamous non-small cell lung cancer 2. Resectable clinical stage II/IIIA (UICC-7) 3. Without previously treatment for lung cancer 4. Age >=20, <75 y 5. ECOG PS 0-1 6. Expected FEV 1.0 > 1.0L after lung resection 7. Adequate organ function 8. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Uncontrollable systemic disease (hyper tension or diabetes mellitus) 2. Current history of hemosputum or hemoptysis 3. Evidence of bleeding diathesis or coagulopathy 4. Cavity in lung tumor or great vessel involvement 5. Current or previous (within the last 1 year) history of cerebrovascular disease 6. Traumatic fracture of un recovery 7. History of active infection 8. Therapeutic anticoagulation; regular use of aspirin (>325 mg/day) 9. Severe GI disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete resection rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse free survival, 2Y,5Y survival, Response rate, Adverse event | — |
Countries
Japan
Contacts
Public Contactkoushi kuroda
UOEH Second Department of Surgery
Outcome results
None listed